 EDISON, N.J., Feb. 16, 2021 GLOBE NEWSWIRE -- Hepion Pharmaceuticals, Inc. NASDAQ:HEPA, a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis NASH, today announced the pricing of its underwritten public offering of 44,200,000 shares of its common stock at a public offering price of 2.00 per share, for gross proceeds of 88.4 million before deducting underwriting discounts, commissions and other offering expenses. All of the shares of common stock are being offered by the Company. 